Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Clears Novel Alzheimer's Blood Test

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

The FDA has cleared PrecivityAD2, the first blood-based biomarker test for Alzheimer's disease diagnosis in adults as young as 40 exhibiting cognitive symptoms. The test measures plasma amyloid beta and tau peptide ratios and is intended to aid in diagnosing Alzheimer's disease as part of a clinical evaluation, not as a standalone screening tool.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ ◆ The Wire takeaway

You can now offer a clinically approved blood test for early Alzheimer's diagnosis to patients from age 40 with cognitive symptoms. This clearance opens a new path to accelerate patient triage and differentiate your services in dementia care.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Digital Healthalzheimersblood-testFDA-clearancediagnosticscognitive-health